Abstract
Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Current Aging Science
Title: The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Volume: 1 Issue: 2
Author(s): R. A. Armstrong
Affiliation:
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Abstract: Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Export Options
About this article
Cite this article as:
Armstrong A. R., The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders, Current Aging Science 2008; 1 (2) . https://dx.doi.org/10.2174/1874609810801020122
DOI https://dx.doi.org/10.2174/1874609810801020122 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research All Cognitive Systems but Speed and Visuospatial Functions Reduce the Effect of CSF Pathology on Other Systems
Current Alzheimer Research Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal VaD - An Integrated Framework for Cognitive Rehabilitation
CNS & Neurological Disorders - Drug Targets Does an Interdisciplinary Network Improve Dementia Care? Results from the IDemUck-Study
Current Alzheimer Research Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Recent Advances in Prion Chemotherapeutics
Infectious Disorders - Drug Targets Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
Current Topics in Medicinal Chemistry Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease
Current Genomics Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Separation and Purification of Small Peptides from Fermented Sesame Meal and Their Antioxidant Activities
Protein & Peptide Letters Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?
Current Molecular Pharmacology GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Affective Temperaments and Mood Disorders: A Review of Current Knowledge
Current Psychiatry Reviews